Will Weak Standard Of Care Lower Approval Bar For PegIntron For Melanoma?
FDA may be more likely to approve Schering-Plough's PegIntron for melanoma based on a modest improvement in relapse-free survival, without an effect on overall survival, with support from its Oncologic Drugs Advisory Committee that the survival advantage for the standard of care - Schering's own Intron A - is questionable
You may also be interested in...
The panel voted 6-4 to recommend approval of the sBLA for PegIntron (peginterferon alfa-2b) for melanoma, and unanimously for Glaxo's Votrient (pazopanib) for advanced renal cell carcinoma.
Enrollment in melanoma drug trials should not be restricted to patients who have failed interferon alfa therapy, FDA's Oncologic Drugs Advisory Committee concluded Feb. 27
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011